Altre lingue Clinuvel Pharmaceuticals Limited

Azioni

CUV

AU000000CUV3

Prodotti farmaceutici

Tempo differito Australian S.E. Altri mercati azionari 00:34:35 16/02/2026			Variaz. 5gg	Var. 1 gen.
11,59 ^AUD	+9,34%		+5,41%	-6,10%

02/02	Clinuvel Pharmaceuticals Prevede la Decisione di Autorizzazione alla Commercializzazione da parte di Health Canada per il Candidato alla Cura della Vitiligine nel Secondo Semestre	MT
12/01	Clinuvel Pharmaceuticals avvia la somministrazione nello studio preclinico con il candidato della piattaforma iniettabile a rilascio controllato	MT

Altre lingue

02/02	Clinuvel Pharmaceuticals Anticipates Health Canada Marketing Authorization Decision For Vitiligo Treatment Candidate in H2
12/01	Clinuvel Pharmaceuticals : Controlled-release injectable peptide platform evaluated in preclinical study
12/01	Clinuvel Pharmaceuticals Starts Dosing in Preclinical Study With Controlled-Release Injectable Platform Candidate
08/01	Clinuvel Pharmaceuticals Says Four Patients Reported Satisfaction in Vitilgo Treatment Study
19/12	Clinuvel Pharmaceuticals Seeks to Uplist American Depositary Receipt Program on Nasdaq
08/12	Clinuvel Pharmaceuticals expands Singapore R&D&I centre to pioneer next-generation peptide therapies
08/12	Clinuvel Expands Research, Development Center in Singapore
02/12	Clinuvel Confirms Mid-2026 Target to File Adrenocorticotropic Hormone Formulation Therapy Candidate with European Regulator
12/11	Clinuvel Pharmaceuticals : Notice of change of interests of substantial holder
03/11	Clinuvel Pharmaceuticals expects U.S. shutdown to impact SEC review timelines
03/11	Clinuvel Pharmaceuticals Expects US Shutdown to Impact ADR Program Upgrade Deadlines
17/10/25	Clinuvel Pharmaceuticals : Managing Director’s address
17/10/25	Clinuvel Pharmaceuticals Limited Seeks Acquisition Opportunities in North America
16/10/25	Clinuvel Says Health Canada Asks for Additional Time, Information for Erythropoietic Protoporphyria Treatment Drug Review
01/10/25	Clinuvel Pharmaceuticals CEO Philippe Wolgen Resumes Role
01/10/25	Clinuvel Pharmaceuticals announces Philippe Wolgen resumes duties as CEO
01/10/25	Clinuvel Pharmaceuticals Limited Announces Chief Executive Officer Changes
29/09/25	CLINUVEL to advance novel pharmaceutical formulations in preclinical program
29/09/25	ASX Midday Sector Update: Healthcare Stocks Climb, Information Technology Sector Down
29/09/25	Clinuvel Pharmaceuticals Progresses Preclinical Program Studying Drug Release Profiles
23/09/25	Clinuvel Pharmaceuticals Says EMA Removes Recommended Maximum Dose for Genetic Disorder Drug
19/09/25	Clinuvel Pharmaceuticals Gives Presentation on Efficacy of Treatment Candidate in Vitiligo Patients, Shares Jump 5%
28/08/25	Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2025
28/08/25	Clinuvel Pharmaceuticals posts FY net income of A$36.2 million
28/08/25	Clinuvel Pharmaceuticals : Annual Report 2025

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Trascrizioni Comunicati stampa Pubblicazioni ufficiali Altre lingue Articoli MarketScreener Analisi MarketScreener Idee di trading

Altre lingue Clinuvel Pharmaceuticals Limited

Azioni

CUV

AU000000CUV3

Prodotti farmaceutici

Altre lingue

Filtri